Bard PowerPort MDL 3081 Status – Judge Campbell, Bellwether Trials and Case Count

Bard PowerPort MDL 3081 is one of the largest active medical device dockets in the federal court system. It centralizes thousands of claims from patients who received implanted port catheters. Plaintiffs say the devices fractured, migrated, or triggered serious infections. The litigation is pending in Arizona federal court. For many cancer patients and long-term infusion patients, the outcome matters a great deal.

What Is the Bard PowerPort MDL 3081 About?

A port catheter is a small device implanted under the skin. It gives clinicians repeated access to a large vein. Doctors use ports for chemotherapy, antibiotics, dialysis support, and contrast imaging. C.R. Bard and Bard Access Systems make the PowerPort line. Becton, Dickinson and Company acquired Bard in 2017. Both companies are named as defendants in the federal litigation.

The claims center on the catheter tubing itself. Bard uses a polyurethane compound marketed as ChronoFlex. Plaintiffs allege the material contains barium sulfate particles that separate over time. As a result, they say, the tubing weakens and develops cracks. Bard disputes these allegations and denies that the device is defective.

The alleged injuries are serious. Reported harms include catheter fracture, device migration into the heart or lungs, bloodstream infection, sepsis, blood clots, deep vein thrombosis, cardiac arrhythmia, and vessel perforation. Some patients required emergency surgery to retrieve fragments. Adverse event reports involving PowerPort devices appear in the FDA MAUDE database. However, MAUDE reports are unverified and do not establish causation on their own.

MDL Case Status and Key Facts

The Judicial Panel on Multidistrict Litigation created this docket in August 2023. Its formal name is In re: Bard Implanted Port Catheter Products Liability Litigation. Judge David G. Campbell of the District of Arizona presides. Judge Campbell is a veteran MDL jurist who also handled the Bard IVC filter litigation.

Case counts change every month. The JPML publishes updated statistics on the first business day of each month. Filings in the Bard PowerPort MDL 3081 have grown steadily since 2023. Typically, docket growth slows once bellwether verdicts arrive.

The first bellwether trial produced a mixed result. In May 2026, an Arizona jury rejected the plaintiff’s failure-to-warn claim. However, the jury could not reach a verdict on design defect or consumer protection claims. The plaintiff then moved for a mistrial. As a result, neither side gained a clean win.

Who Qualifies for the Bard PowerPort MDL 3081?

Eligibility generally starts with the device itself. Claimants typically need medical records confirming implantation of a Bard PowerPort or related Bard implanted port. Common product names include PowerPort MRI, PowerPort ClearVUE, PowerPort SlimPort, PowerPort Duo, and PowerPort isp. Most claims involve devices implanted from roughly 2000 forward.

The second requirement is a documented injury. Qualifying complications generally include catheter fracture or breakage, catheter migration, bloodstream infection or sepsis, thrombosis or blood clots, cardiac injury, and vein perforation. In most cases, the injury must have required medical treatment. Removal or revision surgery strengthens a claim considerably.

Evidence matters more than memory. Helpful documents include implant operative reports, imaging that shows a fracture or migration, hospital admission records, culture results for infections, and the device removal report. For example, a chest X-ray showing a retained catheter fragment is powerful proof. An attorney can request these records for you if you no longer have them.

How to File a Bard PowerPort MDL 3081 Claim

The first step is a consultation with a licensed product liability attorney. Look for a firm with active cases in the Bard PowerPort MDL 3081, not just advertising. Ask how many clients the firm represents in this docket. Ask whether the firm handles cases in-house or refers them out. Most firms in this litigation work on contingency, so no upfront fee applies.

Next comes filing. Many cases are filed directly into the District of Arizona under a direct-filing order. Others are filed in a home district and transferred by the JPML. After filing, plaintiffs must complete a Plaintiff Fact Sheet. This is a detailed sworn questionnaire covering medical history, implant details, treating providers, and injuries. Missing deadlines here can lead to dismissal.

Timing is critical. Each state sets its own statute of limitations for product liability claims. Deadlines commonly range from one to six years. However, many states apply a discovery rule that starts the clock when the injury is discovered. Because these rules are complex and fact-specific, consult an attorney promptly rather than waiting.

Settlement Updates and What to Expect

No global settlement exists in the Bard PowerPort MDL 3081 as of July 2026. Judge Campbell has directed the parties to engage in settlement discussions during 2026. Court-supervised talks are a normal step at this stage. However, a directive to negotiate is not a promise of resolution.

Bellwether results drive settlement value. The first trial gave Bard a defense verdict on warnings. It also left the design defect question unresolved, which preserved a core plaintiff theory. Additional trials are set for August 2026, October 2026, December 2026, and February 2027. Typically, a pattern of verdicts across several trials moves the parties toward global negotiations.

Individual outcomes vary widely, and no compensation is guaranteed. Factors that generally affect value include injury severity, whether surgery was required, permanent harm, medical expenses, lost income, and the strength of causation evidence. Be cautious about advertised settlement figures. Anyone promising a specific number is not describing how this litigation actually works.

State-by-State Considerations

State law still governs many issues inside a federal MDL. Judge Campbell applies each plaintiff’s home state law to substantive questions. As a result, damage caps, comparative fault rules, and statutes of repose differ from case to case. Some states also apply a learned intermediary doctrine that shapes failure-to-warn claims.

Parallel state proceedings also exist. New Jersey designated a multicounty litigation for Bard implanted port cases in October 2024, managed in Bergen County. See the New Jersey Judiciary case information page for filings. Additional cases sit in Arizona state court in Maricopa County. Large plaintiff populations also come from California, Texas, Florida, and Pennsylvania. Review our state guides for California, Texas, Florida, and Pennsylvania.

Frequently Asked Questions

How many cases are pending in the Bard PowerPort MDL 3081?

The JPML reported roughly 3,376 actions pending as of June 1, 2026. More than 3,500 cases have been filed since the docket opened. The number changes monthly as new cases arrive.

Is the Bard PowerPort MDL 3081 a class action?

No. An MDL consolidates individual lawsuits for pretrial handling only. Each plaintiff keeps a separate case with individual damages. Cases can return to their home courts for trial if they are not resolved.

Do I still have a claim if my port was removed years ago?

Possibly. Removal records are often the strongest evidence in these cases. However, the statute of limitations in your state may still apply. You might be eligible, so have a licensed attorney review your records and timeline.

Check If You May Qualify

Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.

Official Sources & Resources

For verified mass tort and MDL information:

• JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
• DOJ: justice.gov — settlement announcements and press releases
• FDA: fda.gov — drug recalls, warning letters, and safety alerts
• CDC: cdc.gov — health condition data and exposure guidelines
• EPA: epa.gov — environmental contamination data
• Cornell LII: law.cornell.edu — plain-English legal definitions

Content last reviewed July 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.

Related Guides

• All Active MDL Cases
• More in This Category
• Tort Reform by State — 50-State Comparison
• All 50 State Tort Reform Guides
• Mass Tort Explainers
• Demographic Guides
• Mass Tort Tips
• Texas Tort Reform Guide
• North Carolina Tort Reform Guide
• New York Tort Reform Guide

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.